Neratinib
Neratinib (pronunciation: neh-RA-ti-nib) is a type of pharmaceutical drug used in the treatment of breast cancer. It is specifically used for the treatment of early-stage, HER2-positive breast cancer.
Etymology
The name "Neratinib" is derived from the combination of parts of two words: "ne" from neoplasms (a type of tumor) and "tinib" which is a common suffix for tyrosine kinase inhibitors.
Pharmacology
Neratinib is a tyrosine kinase inhibitor (TKI), which works by blocking certain proteins in the body that can increase the growth of cancer cells. Specifically, it inhibits the activity of the HER2/neu receptor, a protein that is overexpressed in some types of breast cancer.
Usage
Neratinib is used in the treatment of early-stage, HER2-positive breast cancer, typically after the patient has been treated with trastuzumab. It is also being studied for use in other types of cancer, including non-small cell lung cancer and other solid tumors.
Side Effects
Common side effects of Neratinib include diarrhea, nausea, abdominal pain, fatigue, rash, and mouth sores. Severe side effects can include liver problems and severe diarrhea.
Related Terms
External links
- Medical encyclopedia article on Neratinib
- Wikipedia's article - Neratinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski